Home Newsfeeds RBC Capital Downgrades EOG Resources to Sector Perform

RBC Capital Downgrades EOG Resources to Sector Perform

RBC Capital analyst Scott Hanold downgrades EOG Resources (NYSE:EOG) from Outperform to Sector Perform.

byBenzinga Newsdesk

July 6, 2022

1 minute read

RBC Capital analyst Scott Hanold downgrades EOG Resources (NYSE:EOG) from Outperform to Sector Perform.

Gaotu Techedu Records ~46% Decline In Q3 Revenue

By Shivani Kumaresan

November 22, 12:06 PM

Gaotu Techedu Inc (NYSE:GOTU) reported a third-quarter FY22 sales decline of 45.6% year-on-year to RMB606.2 million ($85.21 million). The revenue decrease…

GOTU

News

Calix Launches Marketing Cloud Plus, The Industry’s Only Acquisition Solution That Enables Any Service Provider To Enhance Real-Time Subscriber Experience Insights With Demographic Data

By Benzinga Newsdesk

October 18, 11:07 AM

As service providers increase their focus on acquiring new subscribers and improving marketing return on investment (ROI), Calix delivers a broadband industry first by helping them enrich their subscriber experience

CALX

FDA
News

AstraZeneca Announced Earlier Imfinzi, Imjudo Approved in Japan for 3 Cancers

By Charles Gross

December 28, 6:12 AM

AstraZeneca's immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung.

AZN

US Stocks Mixed; Jobless Claims Drop More than Projected

By Lisa Levin

May 18, 9:56 AM

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.31% to 33,315.53 while the NASDAQ rose 0.28% to 12,535.19. The S&P 500, also fell, dropping, 0.06% to 4,156.44.

ALIM

RBC Capital Downgrades EOG Resources to Sector Perform

Related Posts

Gaotu Techedu Records ~46% Decline In Q3 Revenue

Calix Launches Marketing Cloud Plus, The Industry’s Only Acquisition Solution That Enables Any Service Provider To Enhance Real-Time Subscriber Experience Insights With Demographic Data

AstraZeneca Announced Earlier Imfinzi, Imjudo Approved in Japan for 3 Cancers

US Stocks Mixed; Jobless Claims Drop More than Projected